Sugi Predict

Sugi Predict / Compounds / SCHEMBL7180437

SCHEMBL7180437

SCHEMBL7180437

Cc1ccc(PC(=O)c2c(C)cccc2C)c(C)c1.[LiH]

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ NFE2L2 Q16236 1/20 0.36
▸ S1PR4 O95977 3/20 0.35
▸ TP53 P04637 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ GAA P10253 2/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ ALOX15 P16050 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ TDP1 Q9NUW8 2/20 0.34
▸ CYP1A2 P05177 2/20 0.34
▸ CYP2A6 P11509 1/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ PARP1 P09874 1/20 0.33
▸ GBA1 P04062 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lithium SCHEMBL7180446 0.97 NFE2L2 (0.36) NFE2L2S1PR4TP53KMT2AGAA
SCHEMBL7185525 0.90 TP53 (0.36) TP53KMT2AGAAALDH1A1HPGD
SCHEMBL7183079 0.90 TYK2 (0.39) KMT2AGAAALDH1A1MEN1RAB9A
SCHEMBL7185635 0.87 ALDH1A1 (0.39) KMT2AGAAALDH1A1MEN1MAPT
SCHEMBL7180684 0.87 S1PR4 (0.38) S1PR4KMT2AGAAALDH1A1HPGD
Lithium SCHEMBL7183080 0.86 TYK2 (0.39) KMT2AGAAALDH1A1MEN1RAB9A
Lithium SCHEMBL7185537 0.86 TP53 (0.36) TP53KMT2AGAAALDH1A1HPGD
Lithium SCHEMBL7185641 0.84 ALDH1A1 (0.39) KMT2AGAAALDH1A1MEN1MAPT
Lithium SCHEMBL7180693 0.83 S1PR4 (0.38) S1PR4KMT2AGAAALDH1A1HPGD
SCHEMBL7188768 0.83 CA12 (0.44) KMT2AGAAALDH1A1MEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 — — US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 — — US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 — — US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 NFE2L2 2548/4885S1PR4 771/4885TP53 3575/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 NFE2L2 2417/4885S1PR4 826/4885TP53 3524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.